ArticleFrontiers in pharmacology2026
In silico high-throughput screening system for INMT activators in prostate cancer therapy.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) is one of the leading causes of cancer-related mortality in men, with castration-resistant prostate cancer (CRPC) posing significant therapeutic challenges due to drug resistance mediated by the androgen receptor (AR) signaling pathway. Indolethylamine-N-methyltransferase (INMT), a tumor-suppressive enzyme downregulated in CRPC, regulates pathways associated with apoptosis and proliferation. Leveraging a structure-based drug design strategy, this study aimed to identify novel INMT agonists for CRPC therapy. Virtual screening of the ChemDiv compound library (guided by the INMT crystal structure, PDB ID: 2A14), combined with molecular docking, MM/GBSA binding energy calculations, and molecular dynamics simulations, identified five candidate compounds. Among these, DMPP-4M stably bound to an allosteric site adjacent to the catalytic domain of INMT via hydrogen bonds, π-cation interactions, and hydrophobic forces.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.